Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 17143

1.

Cdk4/6-inhibitor as a novel therapeutic approach for advanced Bladder Cancer independently of RB1 status.

Rubio C, Martínez-Fernández M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, López-Calderón F, Munera-Maravilla E, Santos M, Bernardini A, Garcia-Escudero R, Lorz C, Gomez-Rodriguez MJ, De Velasco G, Otero Blas I, Villacampa F, Guerrero-Ramos F, Ruiz S, de la Rosa F, Domínguez-Rodríguez S, Real FX, Malats N, Castellano D, Dueñas M, Paramio JM.

Clin Cancer Res. 2018 Sep 21. pii: clincanres.0685.2018. doi: 10.1158/1078-0432.CCR-18-0685. [Epub ahead of print]

PMID:
30242024
2.

Multi-modal meta-analysis of 1494 hepatocellular carcinoma samples reveals significant impact of consensus driver genes on phenotypes.

Chaudhary K, Poirion OB, Lu L, Huang S, Ching T, Garmire LX.

Clin Cancer Res. 2018 Sep 21. pii: clincanres.0088.2018. doi: 10.1158/1078-0432.CCR-18-0088. [Epub ahead of print]

PMID:
30242023
3.

Immunotherapy targeting HPV 16/18 generates potent immune responses in HPV-Associated Head and Neck Cancer.

Aggarwal C, Cohen RB, Morrow MP, Kraynak KA, Sylvester AJ, Knoblock DM, Bauml J, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser MT, Kumar R, Weiner DB, Csiki I, Bagarazzi M.

Clin Cancer Res. 2018 Sep 21. pii: clincanres.1763.2018. doi: 10.1158/1078-0432.CCR-18-1763. [Epub ahead of print]

PMID:
30242022
4.

Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma.

Barry WE, Jackson JR, Asuelime GE, Wu HW, Sun J, Wan Z, Malvar J, Sheard MA, Wang L, Seeger RC, Kim ES.

Clin Cancer Res. 2018 Sep 19. pii: clincanres.1317.2018. doi: 10.1158/1078-0432.CCR-18-1317. [Epub ahead of print]

PMID:
30232225
5.

A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2018 Sep 19. pii: clincanres.1912.2018. doi: 10.1158/1078-0432.CCR-18-1912. [Epub ahead of print]

PMID:
30232224
6.

Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC.

Le X, Puri S, Negrao MV, Nilsson M, Robichaux JP, Boyle TA, Hicks JK, Lovinger K, Roarty EB, Rinsurongkawong W, Tang M, Sun H, Elamin YY, Lacerda L, Lewis J, Lee JJ, Roth JA, Swisher SG, Zhang J, William WN, Glisson BS, Papadimitrakopoulou VA, Gray JE, Heymach JV.

Clin Cancer Res. 2018 Sep 18. pii: clincanres.1542.2018. doi: 10.1158/1078-0432.CCR-18-1542. [Epub ahead of print]

PMID:
30228210
7.

Functional silencing of HSD17B2 in prostate cancer promotes disease progression.

Gao X, Dai C, Huang S, Tang J, Chen G, Li J, Zhu Z, Zhu X, Zhou S, Gao Y, Hou Z, Fang Z, Xu C, Wang J, Wu D, Sharifi N, Li Z.

Clin Cancer Res. 2018 Sep 18. pii: clincanres.2392.2018. doi: 10.1158/1078-0432.CCR-18-2392. [Epub ahead of print]

PMID:
30228209
8.

A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.

Henry KE, Dacek MM, Dilling TR, Caen JD, Fox IL, Evans MJ, Lewis JS.

Clin Cancer Res. 2018 Sep 18. pii: clincanres.1485.2018. doi: 10.1158/1078-0432.CCR-18-1485. [Epub ahead of print]

PMID:
30228208
9.

Epigenetic Therapy with Panobinostat Combined with Bicalutamide Re-challenge in Castration-Resistant Prostate Cancer.

Ferrari AC, Alumkal JJ, Stein MN, Taplin ME, Babb JS, Barnett ES, Gomez-Pinillos A, Liu X, Moore DF, DiPaola RS, Beer TM.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.1589.2018. doi: 10.1158/1078-0432.CCR-18-1589. [Epub ahead of print]

PMID:
30224345
10.

Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, Van Kessel KE, Voskuilen CS, Winters B, Erho NG, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.1106.2018. doi: 10.1158/1078-0432.CCR-18-1106. [Epub ahead of print]

PMID:
30224344
11.

The anatomical location shapes the immune infiltrate in tumors of same etiology and impacts survival.

Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Duurland CL, van Unen V, Höllt T, van der Velden LA, van Egmond SI, Kortekaas K, de Vos van Steenwijk PJ, van Poelgeest MI, Welters MJP, van der Burg SH.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.1749.2018. doi: 10.1158/1078-0432.CCR-18-1749. [Epub ahead of print]

PMID:
30224343
12.

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer.

Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.2062.2018. doi: 10.1158/1078-0432.CCR-18-2062. [Epub ahead of print]

PMID:
30224342
13.

MAVERICC, a randomized, biomarker-stratified, phase 2 study of mFOLFOX6-bevacizumab vs FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer.

Parikh AR, Lee FC, Yau L, Koh H, Knost J, Mitchell EP, Bosanac I, Choong N, Scappaticci FA, Mancao C, Lenz HJ.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.1221.2018. doi: 10.1158/1078-0432.CCR-18-1221. [Epub ahead of print]

PMID:
30224341
14.

Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof of Concept Study in Patients.

Theruvath AJ, Nejadnik H, Muehe AM, Gassert F, Lacayo NJ, Goodman SB, Daldrup-Link HE.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.1687.2018. doi: 10.1158/1078-0432.CCR-18-1687. [Epub ahead of print]

PMID:
30224340
15.

NOTCH1 represses MCL-1 levels in GSI-resistant T-ALL, making them susceptible to ABT-263.

Dastur A, Choi A, Costa C, Yin X, Williams AF, McClanaghan JD, Greenberg M, Roderick JE, Patel NU, Boisvert JL, McDermott U, Garnett MJ, Almenara J, Grant S, Rizzo K, Engelman JA, Kelliher MA, Faber AC, Benes CH.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.0867.2018. doi: 10.1158/1078-0432.CCR-18-0867. [Epub ahead of print]

PMID:
30224339
16.

To cycle or fight - CDK 4/6 inhibitors at the crossroads of anti-cancer immunity.

Ameratunga M, Kipps E, Okines AF, Lopez JS.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.1999.2018. doi: 10.1158/1078-0432.CCR-18-1999. [Epub ahead of print]

PMID:
30224338
17.

USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T cell leukemia.

Jin Q, Martinez CA, Arcipowski KM, Zhu Y, Gutiérrez-Díaz BT, Wang KK, Johnson MR, Volk A, Wang F, Wu J, Grove C, Wang H, Sokirniy I, Thomas PM, Goo YA, Abshiru NA, Hijiya N, Peirs S, Vandamme N, Berx G, Goossens S, Marshall SA, Rendleman EJ, Takahashi YH, Wang L, Rawat R, Bartom ET, Collings CK, Van Vlierberghe P, Bourquin JP, Bornhauser B, Serafin V, Bresolin S, Paganin M, Accordi B, Basso G, Kelleher NL, Weinstock J, Suresh K, Crispino JD, Shilatifard A, Strikoudis A, Mantis C, Kandela I, Kelly S, Ueberheide B, Ntziachristos P.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.1740.2018. doi: 10.1158/1078-0432.CCR-18-1740. [Epub ahead of print]

PMID:
30224337
18.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
19.

AACR Cancer Progress Report 2018: Harnessing Research Discoveries for Patient Benefit.

Sengupta R, Honey K.

Clin Cancer Res. 2018 Sep 15;24(18):4351. doi: 10.1158/1078-0432.CCR-18-2756. No abstract available.

PMID:
30209160
20.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino M.

Clin Cancer Res. 2018 Sep 11. pii: clincanres.1390.2018. doi: 10.1158/1078-0432.CCR-18-1390. [Epub ahead of print]

PMID:
30206165

Supplemental Content

Loading ...
Support Center